Author: Eric Friedman

Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human Pluripotent Stem Cells

MINNEAPOLIS, Nov. 17, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocellâ„¢ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and transISRIB (CEPT) cocktail. This publication outlines a robust and […]